Drugs / GSK835726
last change Aug 2009 re-read 2 minutes ago

GSK835726

Developed for
seasonal allergic rhinitis
Investigated by
GlaxoSmithKline

Trials 1 · a red edge is where a trial was stopped

20082009201020112012201320142015201620172018201920202021202220232024202520262027
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 1 NCT00605852 Oct 2007 → May 2008 seasonal allergic rhinitis GlaxoSmithKline Completed No outcome recorded
Also used as a comparator or background therapy in 2 trials
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 2 NCT00972504 Comparator Jun → Aug 2009 seasonal allergic rhinitis GlaxoSmithKline Completed No outcome recorded
Phase 2 NCT00851344 Comparator Sep → Nov 2008 seasonal allergic rhinitis GlaxoSmithKline Completed No outcome recorded

Evidence & citations 3 cited values

Every value below carries the sentence it was read from. 3 sources stand behind the page.

FieldValueCited text
Known as GSK835726 ClinicalTrials.gov intervention name — accepted as the source's own label NCT00851344
2

NCT00605852

NCT00972504

Action Inhibit “oral H1/H3 dual antagonist compound” NCT00605852
Route Oral “single, escalating oral doses and repeat oral doses (7 days, once daily)” NCT00605852